Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human Trial.

Front Immunol · 2021 · PMC8318801 · PMID 34335606

Europe PMC DOI

hedged sentence

0.0389

closest p · 0.8× alpha

0.0389

boldest claim

The sentences

marginally significantP = 0.03890actually significant

Only a marginally significant increase in anti-IMX313 antibody titers was observed on D74 for Group 2B vs. 2A (P = 0.03890, Kruskal-Wallis test with Dunn’s multiple comparison test), while no difference was evident between the groups on D84 ( Supplementary Figure 4B ).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.